以反復腹瀉為主要臨床表現的特發性嗜酸性粒細胞增多綜合征一例_West China Medical Journal

Authors：

 周強 , 劉楠馨 , 劉作鳳 , 林峰洋 , 成曉敏 ,  賈永前

四川大學華西醫院血液內科（成都 610041）;

Corresponding?author：

賈永前, Email: jia_yq@scu.edu.cn

Keywords：

特發性嗜酸性粒細胞增多綜合征; 腹瀉; 診斷; 治療

DOI：

10.7507/1002-0179.20150455

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 周強, 劉楠馨, 劉作鳳, 林峰洋, 成曉敏, 賈永前. 以反復腹瀉為主要臨床表現的特發性嗜酸性粒細胞增多綜合征一例. West China Medical Journal, 2015, 30(8): 1593-1594. doi: 10.7507/1002-0179.20150455 Copy

1.	Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome:analysis of fourteen cases with review of the literature[J]. Medicine, 1975, 54(1):1-27.
2.	Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues[M]. 4th ed. Geneva:World Health Organization, 2008:67-73.
3.	Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome[J]. Annals of Internal Medicine, 1978, 89(2):167-172.
4.	Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia:point-of-care diagnostic algorithm and treatment update[J]. Mayo Clin Proc, 2010, 85(2):158-164.
5.	Helbig G, Stella-Ho?owiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients[J]. Br J Haematol, 2008, 141(2):200-204.
6.	Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFR and FIP1L1 genes as a therapeutic target of imanitib in idiopathic hypereosinophilic syndrome[J]. N Engl J Med, 2003, 348(13):1201-1214.
7.	Klion AD, Robyn J, Maric l, et al. Relapse following discontinuation of imatinib mesylate therapy for FIPlLl/PDGFRA-positive chronic eosinophilic leukemia:implications for optimal dosing[J]. Blood, 2007, 110(10):3552-3556.
8.	David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders[J]. Blood, 2007, 109(1):61-64.
9.	Simon D, Salemi S, Yousefi S, et al. Primary resistance to imatinib in Fipl-like1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia[J]. J Allergy Clin Immunol, 2008, 121(4):1054-1056.
10.	Malcovati, L, La Starza R, Merante S, et al. Hypereosinophilic syndrome and cyclic oscillations in blood cell counts. A clonal disorder of hematopoiesis originating in a pluripotent stem cell[J]. Haematologica, 2004, 89(4):497-499.
11.	Needleman SW, Mane SM, Gutheil JC, et al. Hypereosinophilic syndrome with evolution to myeloproliferative disorder:temporal relationship to loss of Y chromosome and c-N-ras activation[J]. Hematol Pathol, 1990, 4(3):149-155.
12.	Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases[J]. Ann Med Interne (Paris), 1989, 140(4):253-257.
13.	Vincent EH, Joe CF, Zhou YW, et al. Hypereosinophilic syndrome[M]. Emedicine Hematology, 2004:131.

1. Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome:analysis of fourteen cases with review of the literature[J]. Medicine, 1975, 54(1):1-27.
2. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues[M]. 4th ed. Geneva:World Health Organization, 2008:67-73.
3. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome[J]. Annals of Internal Medicine, 1978, 89(2):167-172.
4. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia:point-of-care diagnostic algorithm and treatment update[J]. Mayo Clin Proc, 2010, 85(2):158-164.
5. Helbig G, Stella-Ho?owiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients[J]. Br J Haematol, 2008, 141(2):200-204.
6. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFR and FIP1L1 genes as a therapeutic target of imanitib in idiopathic hypereosinophilic syndrome[J]. N Engl J Med, 2003, 348(13):1201-1214.
7. Klion AD, Robyn J, Maric l, et al. Relapse following discontinuation of imatinib mesylate therapy for FIPlLl/PDGFRA-positive chronic eosinophilic leukemia:implications for optimal dosing[J]. Blood, 2007, 110(10):3552-3556.
8. David M, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders[J]. Blood, 2007, 109(1):61-64.
9. Simon D, Salemi S, Yousefi S, et al. Primary resistance to imatinib in Fipl-like1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia[J]. J Allergy Clin Immunol, 2008, 121(4):1054-1056.
10. Malcovati, L, La Starza R, Merante S, et al. Hypereosinophilic syndrome and cyclic oscillations in blood cell counts. A clonal disorder of hematopoiesis originating in a pluripotent stem cell[J]. Haematologica, 2004, 89(4):497-499.
11. Needleman SW, Mane SM, Gutheil JC, et al. Hypereosinophilic syndrome with evolution to myeloproliferative disorder:temporal relationship to loss of Y chromosome and c-N-ras activation[J]. Hematol Pathol, 1990, 4(3):149-155.
12. Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases[J]. Ann Med Interne (Paris), 1989, 140(4):253-257.
13. Vincent EH, Joe CF, Zhou YW, et al. Hypereosinophilic syndrome[M]. Emedicine Hematology, 2004:131.

Previous Article
三陰乳腺癌抗血管生成治療進展及影像學評價
Next Article
邊緣葉腦炎正電子發射斷層掃描/CT及MRI影像特征一例

West China Medical Journal

以反復腹瀉為主要臨床表現的特發性嗜酸性粒細胞增多綜合征一例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content